Clinical Advances in

Wilson Disease: A Journey From Suspicion to Diagnosis to Management

CME Activities

Wilson Disease: What's on the Horizon?

Medscape Education, April 2023

Did you know that despite treatment, patients with Wilson disease (WD) can experience persistent symptoms, irreversible neurologic deficits, and treatment failure?

0.50 CME
Latest Advances in Wilson Disease: Is Your Practice Ready?

Medscape Education, March 2023

Are you up-to-date on the recommendations for diagnosing and managing Wilson disease (WD)?

0.25 CME

0.25 ABIM MOC
Management of Wilson Disease: What Do the New Recommendations Say?

Medscape Education, March 2023

Did you know that the new recommendations for WD highlight updates on diagnostic algorithms, treatment monitoring tools and neuropsychiatric involvement in WD?

0.50 CME

0.50 ABIM MOC

Detecting Wilson Disease

Clinical Manifestations Accompanying Copper Accumulation

Resources

Downloadable Slide Kit

Clinical Advances in Wilson Disease: A Journey From Suspicion to Diagnosis to Management

Clinical Reference

Steering Committee

Karl Heinz Weiss, MD

Steering Committee Member Chair

Professor of Internal Medicine and Gastroenterology
Chief Physician of the Medical Clinic
Salem Hospital
Heidelberg, Germany

Bio Video

Anna Członkowska, MD, PhD

Professor at the Department of Neurology
Institute of Psychiatry and Neurology
Warsaw, Poland

Bio Video

Aurelia Poujois, MD

National Coordinator of the Centre de Référence for Wilson Disease
Department of Neurology
Hospital Foundation Adolphe de Rothschild
Paris, France

Anil Dhawan, MBBS, MD, FRCPCH

Professor of Pediatric Hepatology
King's College London
London, United Kingdom

Bio Video

Danny Bega, MD

Associate Professor of Neurology
Northwestern University
Chicago, Illinois, United States

Bio Video

Paula C Zimbrean, MD, FAPA, FACLP

Associate Professor of Psychiatry and Surgery
Yale University School of Medicine
New Haven, Connecticut, US

Bio Video

Steering Committee

Karl Heinz Weiss, MD

Steering Committee Chair

Has the following relevant financial relationships:

Consultant or advisor for: Alexion; Bayer; Orphalan; Pfizer; Ultragenyx; Univar BV; Vivet Therapeutics

Anna Członkowska, MD, PhD

Has no relevant financial relationships.

Aurelia Poujois, MD

Has the following relevant financial relationships:

Consultant or advisor for: Alexion; Orphalan; Univar; Vivet Therapeutics

Speaker or member of speakers bureau for: Alexion; Orphalan; Univar

Research funding from: AddMedica; Merz Pharma; Orphalan

Anil Dhawan, MBBS, MD, FRCPCH

Has no relevant financial relationships.

Danny Bega, MD

Has the following relevant financial relationships:

Consultant or advisor for: Alexion Pharmaceuticals; Acsel Health; Clearview Consulting; Guidepoint; GE Healthcare; Genentech Inc; LEK Consulting; Novartis; Teva Pharmaceuticals; Ultragenyx Pharmaceuticals

Speaker or member of speakers bureau for: Abbvie; Adamas Pharmaceuticals; Acorda Therapeutics, Kyowa Kirin; Neurocrine Biosciences; Sunovion; Teva Pharmaceuticals

Paula C Zimbrean, MD, FAPA, FACLP

Has the following relevant financial relationships:

Research funding from: Alexion

Contracted researcher for: Alexion